Genetic Variants and Risk of Chronic Kidney Disease
Genetic factors are increasingly recognized to contribute to the risk of chronic kidney disease, and important differences in the risk of progression to end-stage renal disease have been observed in different racial groups (1) . In particular, African American patients have 4-to 5-fold more kidney failure than white patients. Identifying genetic factors contributing to this increased risk is of major importance to address renal disease progression (2). Renal Insufficiency Cohort (CRIC, 2955 patients) (3). The high-risk group was defined as having 2 copies of high risk variants, whereas the low-risk group had 0 or 1 copy. A consistent and robust association between the presence of APOL1 risk variants and higher rates of end-stage renal disease and progression of chronic kidney disease was observed in black patients as compared with white patients, regardless of diabetes status. In the AASK study for instance, patients with 2 copies of APOL1 risk variants were twice as likely to progress to the composite of end-satge renal disease or a reduction of 50% in the eGFR from baseline over a median follow-up of 9 years. Of note, the progression of CKD was not influenced by blood pressure control (as compared to the APOL1 status), and there was no interaction between the APOL1 genotype and treatment with an ACE inhibitor in the black population.
Seminal investigations led by
These studies confirm the robust association of renal risk variants in APOL1 with higher rates of end-stage renal disease and progression of chronic non-diabetic kidney disease in black patients as compared with white patients. They also demonstrate that, in a context of recent selection pressure against pathogens in African Americans, a risk variant that is relatively frequent may also have a large effect size (2) . Future research will need to address the mechanism by which ApoL1 cause renal disease (we only known that ApoL1 is expressed in the glomerulus), as well as the inconsistent effect of APOL1 genotype in patients with diabetic kidney disease.
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